Food & Drug Administration

Revive Therapeutics Granted FDA Orphan Drug Designation

According to a recent announcement made by Revive Therapeutics, the company has been granted an FDA Orphan Drug Designation for the use of cannabidiol (“CBD”) in preventing ischemia and reperfusion injury (“IRI”) — both of which can result from solid organ transplantation. Under the Orphan Drug Act of 1983, the FDARead More →

CBD-Derived Epidiolex Gains FDA Approval for Epilepsy

In an historic first, the U.S. Food and Drug Administration approved the drug Epidiolex for the treatment of children with epilepsy. The FDA-approved prescription of Epidiolex is specifically intended for the treatment of two kinds of very severe epilepsy, namely: Dravet  syndrome and Lennox-Gastaut Syndrome. GW Pharmaceuticals, based in the UK, manufactures theRead More →